Molecular Aspects and Therapeutic Implications of Herbal Compounds Targeting Different Types of Cancer

Due to genetic changes in DNA (deoxyribonucleic acid) sequences, cancer continues to be the second most prevalent cause of death. The traditional target-directed approach, which is confronted with the importance of target function in healthy cells, is one of the most significant challenges in anticancer research. Another problem with cancer cells is that they experience various mutations, changes in gene duplication, and chromosomal abnormalities, all of which have a direct influence on the potency of anticancer drugs at different developmental stages. All of these factors combine to make cancer medication development difficult, with low clinical licensure success rates when compared to other therapy categories. The current review focuses on the pathophysiology and molecular aspects of common cancer types. Currently, the available chemotherapeutic drugs, also known as combination chemotherapy, are associated with numerous adverse effects, resulting in the search for herbal-based alternatives that attenuate resistance due to cancer therapy and exert chemo-protective actions. To provide new insights, this review updated the list of key compounds that may enhance the efficacy of cancer treatment.

[1]  H. Abrahamse,et al.  Multi-Target Potential of Berberine as an Antineoplastic and Antimetastatic Agent: A Special Focus on Lung Cancer Treatment , 2022, Cells.

[2]  A. Valdiani,et al.  Andrographis paniculata extract as an immunity modulator against cancer via telomerase inhibition , 2022, 3 Biotech.

[3]  J. Sharifi‐Rad,et al.  Anticancer potential of alkaloids: a key emphasis to colchicine, vinblastine, vincristine, vindesine, vinorelbine and vincamine , 2022, Cancer cell international.

[4]  Dileep Kumar,et al.  Exploring the structural and functional requirements of Phyto-compounds and their synthetic scaffolds as anticancer agents: medicinal chemistry perspective , 2022, Pharmacological Research - Modern Chinese Medicine.

[5]  Kyu Bong Cho,et al.  A Review of Natural Products for Prevention of Acute Kidney Injury , 2021, Medicina.

[6]  I. S. Cogno,et al.  Light-activated green drugs: How we can use them in photodynamic therapy and mass-produce them with biotechnological tools , 2021 .

[7]  M. Bijak,et al.  The Green Anti-Cancer Weapon. The Role of Natural Compounds in Bladder Cancer Treatment , 2021, International journal of molecular sciences.

[8]  Yang Ouyang,et al.  Chalcone Derivatives: Role in Anticancer Therapy , 2021, Biomolecules.

[9]  G. Zengin,et al.  Current Perspective on the Natural Compounds and Drug Delivery Techniques in Glioblastoma Multiforme , 2021, Cancers.

[10]  S. Hua,et al.  Perspectives and controversies regarding the use of natural products for the treatment of lung cancer , 2021, Cancer medicine.

[11]  I. Heydari,et al.  Association of Serum and Tumor Tissue microRNA Profile with Aggressiveness of Papillary Thyroid Carcinoma in an Iranian Population , 2021 .

[12]  A. Daneshkhah,et al.  Clinical effects of curcumin in enhancing cancer therapy: A systematic review , 2020, BMC Cancer.

[13]  R. Derynck,et al.  TGFβ biology in cancer progression and immunotherapy , 2020, Nature Reviews Clinical Oncology.

[14]  N. Agarwal,et al.  Advanced Prostate Cancer: Treatment Advances and Future Directions. , 2020, Trends in cancer.

[15]  M. Vinceti,et al.  Deregulated PTEN/PI3K/AKT/mTOR signaling in prostate cancer: Still a potential druggable target? , 2020, Biochimica et biophysica acta. Molecular cell research.

[16]  J. Humm,et al.  Comparing the intra-tumoral distribution of Gemcitabine, 5-Fluorouracil, and Capecitabine in a murine model of pancreatic ductal adenocarcinoma , 2020, PloS one.

[17]  Y. Ghasemi,et al.  Quercetin and cancer: new insights into its therapeutic effects on ovarian cancer cells , 2020, Cell & Bioscience.

[18]  M. Morassi,et al.  Late intracranial metastasis from adenoid-cystic carcinoma of the parotid gland: Imaging, histologic and molecular features. , 2020, Current problems in cancer.

[19]  Hai-hua Luo,et al.  Pembrolizumab plus allogeneic NK cells in advanced non-small cell lung cancer patients. , 2020, The Journal of clinical investigation.

[20]  P. Limonta,et al.  Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets , 2020, Cells.

[21]  James X. Sun,et al.  Principles of Targeted Therapy for Melanoma. , 2020, The Surgical clinics of North America.

[22]  A. Onitilo,et al.  Principles of Immunotherapy in Melanoma. , 2020, The Surgical clinics of North America.

[23]  Marcus Krüger,et al.  Multikinase Inhibitor Treatment in Thyroid Cancer , 2019, International journal of molecular sciences.

[24]  Y. Kikushige Pathophysiology of chronic lymphocytic leukemia and human B1 cell development , 2019, International Journal of Hematology.

[25]  M. Cabanillas,et al.  Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. , 2019, Endocrine reviews.

[26]  H. Gurney,et al.  Clinical concepts for cabazitaxel in the management of metastatic castration‐resistant prostate cancer , 2019, Asia-Pacific journal of clinical oncology.

[27]  V. V. Padma,et al.  The cytoprotective and anti-cancer potential of bisbenzylisoquinoline alkaloids from Nelumbo nucifera. , 2019, Current topics in medicinal chemistry.

[28]  P. Vaupel,et al.  NK cell-based therapeutics for lung cancer , 2019, Expert opinion on biological therapy.

[29]  P. Marchetti,et al.  Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents. , 2019, European journal of pharmacology.

[30]  M. Gleave,et al.  Towards precision oncology in advanced prostate cancer , 2019, Nature Reviews Urology.

[31]  T. Habermann,et al.  Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era , 2019, Leukemia & lymphoma.

[32]  M. Zeng,et al.  ALKATI interacts with c-Myc and promotes cancer stem cell-like properties in sarcoma , 2019, Oncogene.

[33]  P. Queirolo,et al.  Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy. , 2019, Seminars in cancer biology.

[34]  P. Åman,et al.  IGF2/IGF1R Signaling as a Therapeutic Target in MYB-Positive Adenoid Cystic Carcinomas and Other Fusion Gene-Driven Tumors , 2019, Cells.

[35]  J. Molina,et al.  Non-Small Cell Lung Cancer: Epidemiology, Screening, Diagnosis, and Treatment. , 2019, Mayo Clinic proceedings.

[36]  M. R. Ruocco,et al.  Metabolic flexibility in melanoma: a potential therapeutic target. , 2019, Seminars in cancer biology.

[37]  M. Gertz,et al.  Inotersen for the treatment of adults with polyneuropathy caused by hereditary transthyretin-mediated amyloidosis , 2019, Expert review of clinical pharmacology.

[38]  T. Ramachandra,et al.  Phytochemical and Pharmacological Importance of Turmeric (Curcuma longa): A Review , 2019 .

[39]  H. Yamawaki,et al.  Emerging Roles of C-Myc in Cancer Stem Cell-Related Signaling and Resistance to Cancer Chemotherapy: A Potential Therapeutic Target Against Colorectal Cancer , 2019, International journal of molecular sciences.

[40]  C. Porta,et al.  The adjuvant treatment of kidney cancer: a multidisciplinary outlook , 2019, Nature Reviews Nephrology.

[41]  T. Kinoshita,et al.  Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review , 2019, International journal of molecular sciences.

[42]  N. De Regge,et al.  Porcine NK Cells Stimulate Proliferation of Pseudorabies Virus-Experienced CD8+ and CD4+CD8+ T Cells , 2019, Front. Immunol..

[43]  J. Palefsky,et al.  HPV-Associated Anal Cancer in the HIV/AIDS Patient. , 2018, Cancer treatment and research.

[44]  R. Perez-soler,et al.  Nanoparticle albumin bound-paclitaxel for treatment of advanced non-small cell lung cancer: an evaluation of the clinical evidence , 2018, Expert opinion on pharmacotherapy.

[45]  M. Gertz,et al.  Daratumumab for the treatment of AL amyloidosis , 2018, Leukemia & lymphoma.

[46]  A. Jemal,et al.  Cancer statistics, 2019 , 2019, CA: a cancer journal for clinicians.

[47]  Christiana Lucas,et al.  An overview of Human Papillomavirus (HPV) as an etiological factor of the anal cancer. , 2019, Journal of infection and public health.

[48]  A. Jeyasekharan,et al.  ROS and the DNA damage response in cancer , 2018, Redox biology.

[49]  M. Jolly,et al.  Chronic Obstructive Pulmonary Disease and Lung Cancer: Underlying Pathophysiology and New Therapeutic Modalities , 2018, Drugs.

[50]  F. Cavalli,et al.  Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomis , 2018, The Lancet. Oncology.

[51]  L. Shan,et al.  The efficacy and safety of nivolumab, pembrolizumab, and atezolizumab in treatment of advanced non-small cell lung cancer. , 2018, Discovery medicine.

[52]  Matthew M. Symer,et al.  Recent advances in the management of anal cancer , 2018, F1000Research.

[53]  D. Frezzetti,et al.  Pharmacokinetic drug evaluation of palbociclib for the treatment of breast cancer , 2018, Expert opinion on drug metabolism & toxicology.

[54]  Carola Berking,et al.  Melanoma , 2018, The Lancet.

[55]  D. Davar,et al.  MEK inhibitors for the treatment of NRAS mutant melanoma , 2018, Drug design, development and therapy.

[56]  R. Burbano,et al.  Molecular biology as a tool for the treatment of cancer , 2018, Clinical and Experimental Medicine.

[57]  Yvonne E. Moussa,et al.  The side effects of platinum-based chemotherapy drugs: a review for chemists. , 2018, Dalton transactions.

[58]  F. Sclafani,et al.  Systemic Therapies for Advanced Squamous Cell Anal Cancer , 2018, Current Oncology Reports.

[59]  S. Asokan,et al.  Pharmacological benefits of neferine ‐ A comprehensive review , 2018, Life sciences.

[60]  R. Weiss Metabolomics and Metabolic Reprogramming in Kidney Cancer. , 2018, Seminars in nephrology.

[61]  Raju Dash,et al.  Natural Products for the Management and Prevention of Breast Cancer , 2018, Evidence-based complementary and alternative medicine : eCAM.

[62]  R. Hasina,et al.  Genomics of mucoepidermoid and adenoid cystic carcinomas , 2018, Laryngoscope investigative otolaryngology.

[63]  A. Čumová,et al.  Natural compounds and combination therapy in colorectal cancer treatment. , 2018, European journal of medicinal chemistry.

[64]  G. Bhagat,et al.  BCL6 as a therapeutic target for lymphoma , 2018, Expert opinion on therapeutic targets.

[65]  Yu-Ying He,et al.  Mechanisms and prevention of UV‐induced melanoma , 2018, Photodermatology, photoimmunology & photomedicine.

[66]  G. Nasti,et al.  Metastatic Colorectal Cancer: Role of Target Therapies and Future Perspectives. , 2017, Current cancer drug targets.

[67]  Md Soriful Islam,et al.  Extracellular matrix in uterine leiomyoma pathogenesis: a potential target for future therapeutics , 2018, Human reproduction update.

[68]  A. Lenis,et al.  Adjuvant Therapy for High Risk Localized Kidney Cancer: Emerging Evidence and Future Clinical Trials , 2018, The Journal of urology.

[69]  I. Durán,et al.  Systemic treatment of renal cell cancer: A comprehensive review. , 2017, Cancer treatment reviews.

[70]  M. McDonald,et al.  Sclerostin: an Emerging Target for the Treatment of Cancer-Induced Bone Disease , 2017, Current Osteoporosis Reports.

[71]  M. Morrison,et al.  Oral Microbiome: A New Biomarker Reservoir for Oral and Oropharyngeal Cancers , 2017, Theranostics.

[72]  Michael I. Seider,et al.  Everolimus to treat aggressive retinal astrocytic hamartoma in tuberous sclerosis complex. , 2017, Journal of AAPOS : the official publication of the American Association for Pediatric Ophthalmology and Strabismus.

[73]  E. Abdel-Sattar,et al.  Chemical and Biological Investigation of Ochrosia elliptica Labill. Cultivated in Egypt , 2017 .

[74]  Serguei A Castaneda,et al.  Radiotherapy for Anal Cancer: Intensity-Modulated Radiotherapy and Future Directions. , 2017, Surgical oncology clinics of North America.

[75]  Lovelace J. Luquette,et al.  A Pan-Cancer Proteogenomic Atlas of PI3K/AKT/mTOR Pathway Alterations. , 2017, Cancer cell.

[76]  S. Batra,et al.  MUC4 mucin- a therapeutic target for pancreatic ductal adenocarcinoma , 2017, Expert opinion on therapeutic targets.

[77]  M. Morris,et al.  Simultaneous quantitation of abiraterone, enzalutamide, N‐desmethyl enzalutamide, and bicalutamide in human plasma by LC–MS/MS , 2017, Journal of pharmaceutical and biomedical analysis.

[78]  N. Dawson,et al.  Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy. , 2017, American health & drug benefits.

[79]  K. Flaherty,et al.  Targeted agents and immunotherapies: optimizing outcomes in melanoma , 2017, Nature Reviews Clinical Oncology.

[80]  Baoan Chen,et al.  β-Elemene: Mechanistic Studies on Cancer Cell Interaction and Its Chemosensitization Effect , 2017, Front. Pharmacol..

[81]  J. Munkley Glycosylation is a global target for androgen control in prostate cancer cells. , 2017, Endocrine-related cancer.

[82]  Hong-Yo Kang,et al.  MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer , 2017, International journal of molecular sciences.

[83]  Walter J Curran,et al.  Lung cancer: current therapies and new targeted treatments , 2017, The Lancet.

[84]  J. Cicenas,et al.  KRAS, NRAS and BRAF mutations in colorectal cancer and melanoma , 2017, Medical Oncology.

[85]  Ming Sun,et al.  Long noncoding RNA ZFAS1 promotes gastric cancer cells proliferation by epigenetically repressing KLF2 and NKD2 expression , 2016, Oncotarget.

[86]  F. Liu-Smith,et al.  UV-Induced Molecular Signaling Differences in Melanoma and Non-melanoma Skin Cancer. , 2017, Advances in experimental medicine and biology.

[87]  A. Gratchev,et al.  Tumor Associated Macrophages in Kidney Cancer , 2016, Analytical cellular pathology.

[88]  A. Polizzi,et al.  Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies , 2016, Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale.

[89]  Hui Liu,et al.  International Journal of Molecular Sciences the Fascinating Effects of Baicalein on Cancer: a Review , 2022 .

[90]  S. Vota,et al.  Amyloidosis and its management: Amyloid neuropathies. , 2016, Current problems in cancer.

[91]  W. Yarbrough,et al.  Clinical and molecular insights into adenoid cystic carcinoma: Neural crest‐like stemness as a target , 2016, Laryngoscope investigative otolaryngology.

[92]  R. Ferrarotto,et al.  MYB-fusions and other potential actionable targets in adenoid cystic carcinoma , 2016, Current opinion in oncology.

[93]  Zongming Jiang,et al.  Blocking mammalian target of rapamycin alleviates bone cancer pain and morphine tolerance via µ‐opioid receptor , 2016, International journal of cancer.

[94]  C. Moskaluk,et al.  Adenoid cystic carcinoma: A review of recent advances, molecular targets, and clinical trials , 2015, Head & neck.

[95]  C. Rasch,et al.  Induction chemotherapy with docetaxel/cisplatin/5-fluorouracil followed by randomization to two cisplatin-based concomitant chemoradiotherapy schedules in patients with locally advanced head and neck cancer (CONDOR study) (Dutch Head and Neck Society 08-01): A randomized phase II study. , 2016, European journal of cancer.

[96]  B. Carneiro,et al.  Adenoid cystic carcinoma: current therapy and potential therapeutic advances based on genomic profiling , 2015, Oncotarget.

[97]  H. Ahmad,et al.  Anticancer Effects of Extracts from the Fruit of Morinda Citrifolia (Noni) in Breast Cancer Cell Lines , 2015, Drug Research.

[98]  S. Rosenberg,et al.  Adoptive cell transfer as personalized immunotherapy for human cancer , 2015, Science.

[99]  Kevin A. Henry,et al.  Annual Report to the Nation on the Status of Cancer, 1975-2011, Featuring Incidence of Breast Cancer Subtypes by Race/Ethnicity, Poverty, and State , 2015, Journal of the National Cancer Institute.

[100]  A. Colevas,et al.  Differentiated thyroid cancer: focus on emerging treatments for radioactive iodine-refractory patients. , 2015, The oncologist.

[101]  S. Oh,et al.  Andrographolide and analogues in cancer prevention. , 2015, Frontiers in bioscience.

[102]  K. Straif,et al.  Betel quid chewing and the risk of oral and oropharyngeal cancers: A meta‐analysis with implications for cancer control , 2014, International journal of cancer.

[103]  P. He,et al.  20(s)-ginsenoside Rg3 promotes apoptosis in human ovarian cancer HO-8910 cells through PI3K/Akt and XIAP pathways , 2014, Tumor Biology.

[104]  Y. Fukui Mechanisms behind signet ring cell carcinoma formation. , 2014, Biochemical and biophysical research communications.

[105]  Josias H. Hamman,et al.  Review of Natural Compounds for Potential Skin Cancer Treatment , 2014, Molecules.

[106]  T. Dorff,et al.  Novel tyrosine kinase inhibitors for renal cell carcinoma , 2014, Expert review of clinical pharmacology.

[107]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[108]  V. Jordan,et al.  Send Orders of Reprints at Reprints@benthamscience.net the Discovery and Development of Selective Estrogen Receptor Modulators (serms) for Clinical Practice the Biological Basis of Serm Action: Target Tissue Specific Actions , 2022 .

[109]  L. Pusztai,et al.  Cancer heterogeneity: implications for targeted therapeutics , 2013, British Journal of Cancer.

[110]  Amy M. Pick,et al.  Pazopanib for the treatment of metastatic renal cell carcinoma. , 2012, Clinical therapeutics.

[111]  M. Gore,et al.  Cediranib monotherapy in patients with advanced renal cell carcinoma: results of a randomised phase II study. , 2012, European journal of cancer.

[112]  A. Ravaud,et al.  Targeted Therapies in Metastatic Renal Cell Carcinoma: Overview of the Past Year , 2012, Current Urology Reports.

[113]  Han Yong Choi,et al.  The epidemiology of renal cell carcinoma. , 2011, European urology.

[114]  David Needham,et al.  Nanoscale Drug Delivery and Hyperthermia: The Materials Design and Preclinical and Clinical Testing of Low Temperature-Sensitive Liposomes Used in Combination with Mild Hyperthermia in the Treatment of Local Cancer. , 2011, The open nanomedicine journal.

[115]  Rosette Lidereau,et al.  Gene Expression Profiling Reveals New Aspects of PIK3CA Mutation in ERalpha-Positive Breast Cancer: Major Implication of the Wnt Signaling Pathway , 2010, PloS one.

[116]  B. Moore,et al.  Salinosporamide natural products: Potent 20 S proteasome inhibitors as promising cancer chemotherapeutics. , 2010, Angewandte Chemie.

[117]  R. Lothe,et al.  DNA Sequence Profiles of the Colorectal Cancer Critical Gene Set KRAS-BRAF-PIK3CA-PTEN-TP53 Related to Age at Disease Onset , 2010, PloS one.

[118]  L. Standish,et al.  Polysaccharide Krestin Is a Novel TLR2 Agonist that Mediates Inhibition of Tumor Growth via Stimulation of CD8 T Cells and NK Cells , 2010, Clinical Cancer Research.

[119]  V. Vogel The NSABP Study of Tamoxifen and Raloxifene (STAR) trial , 2009, Expert review of anticancer therapy.

[120]  M. D. De Bruin,et al.  Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. , 2008, Journal of the National Cancer Institute.

[121]  R. Ganju,et al.  Medicinal plants and cancer chemoprevention. , 2008, Current drug metabolism.

[122]  M. Bremer,et al.  Preoperative Paclitaxel/Carboplatin Radiochemotherapy for Stage III/IV Resectable Oral and Oropharyngeal Cancer: Seven-Year Follow-Up of a Phase II Trial , 2008, Oncology.

[123]  R. Salgia,et al.  Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion , 2007, British Journal of Cancer.

[124]  A. Ng,et al.  Diffuse large B-cell lymphoma. , 2007, Seminars in radiation oncology.

[125]  Ram H Datar,et al.  Molecular pathways in invasive bladder cancer: new insights into mechanisms, progression, and target identification. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  Ronald A. DePinho,et al.  Hepatocellular carcinoma pathogenesis: from genes to environment , 2006, Nature Reviews Cancer.

[127]  M. Hussein Ultraviolet radiation and skin cancer: molecular mechanisms , 2005, Journal of cutaneous pathology.

[128]  V. Mazzaferro,et al.  Resection and Liver Transplantation for Hepatocellular Carcinoma , 2005, Seminars in liver disease.

[129]  M. Ellis,et al.  Letrozole inhibits tumor proliferation more effectively than tamoxifen independent of HER1/2 expression status. , 2003, Cancer research.

[130]  D. Goodsell The molecular perspective: tamoxifen and the estrogen receptor. , 2002, Stem cells.

[131]  Z. Naito,et al.  [Expression and intracytoplasmic signal transduction pathway of fibroblast growth factor (FGF)-10 in human cervical cancer cell lines]. , 2001, Journal of Nippon Medical School = Nippon Ika Daigaku zasshi.

[132]  A. Arboix [Cerebrovascular disease in the cancer patient]. , 2000, Revista de neurología (Ed. impresa).

[133]  J. Posner,et al.  Neurological complications of systemic cancer. , 1971, The Medical clinics of North America.

[134]  J. Knowelden,et al.  Cancer Epidemiology and Prevention , 1976, British Journal of Cancer.

[135]  J. Haybittle,et al.  Early breast cancer. , 1970, British medical journal.